The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors

The discovery of colchicine-SAHA hybrids as a new class of antitumor agents

(2013) Xuan Zhang et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases

(2012) Thomas Beckers et al.   MedChemComm

BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities

(2010) Qi-Ming Sun et al.   CANCER BIOLOGY & THERAPY

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

(2010) Cheng-Jung Lai et al.   CANCER RESEARCH

Inhibitors of HDACs - Effective Drugs Against Cancer?

(2010) S. Muller et al.   CURRENT CANCER DRUG TARGETS

Macrocyclic Histone Deacetylase Inhibitors

(2010) Sandra C. Mwakwari et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors

(2010) Cliona Grant et al.   Expert Review of Anticancer Therapy

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

(2010) Xiong Cai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity

(2010) Siavosh Mahboobi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines

(2010) Bhaswati Sarcar et al.   JOURNAL OF NEURO-ONCOLOGY

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

(2010) James E. Bradner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases†

(2009) Siavosh Mahboobi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis

(2009) F. Bruzzese et al.   MOLECULAR CANCER THERAPEUTICS

HDAC2: a critical factor in health and disease

(2009) Oliver H. Krämer   TRENDS IN PHARMACOLOGICAL SCIENCES

Histone deacetylase inhibitors in cancer therapy

(2008) Min-Jung Lee et al.   CURRENT OPINION IN ONCOLOGY

The ErbB kinase domain: Structural perspectives into kinase activation and inhibition

(2008) Ron Bose et al.   EXPERIMENTAL CELL RESEARCH

Non-Peptide Macrocyclic Histone Deacetylase Inhibitors

(2008) Adegboyega K. Oyelere et al.   JOURNAL OF MEDICINAL CHEMISTRY